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Abstract
Background: Resistance to chemotherapy is the major cause of failure in breast cancer treatment. Recent studies suggest
that secreted proteins may play important roles in chemoresistance. We sought to systematically characterize secreted
proteins associated with drug resistance, which may represent potential serum biomarkers or novel drug targets.
Methodology/Principal Findings: In the present work, we adopted the proteomic strategy of one-dimensional gel
electrophoresis followed by liquid chromatography-tandem mass spectrometry to compare the secretome of MCF-7 and
doxorubicin-resistant MCF-7/Dox. A total of 2,084 proteins were identified with at least two unique peptides in the
conditioned media of two cell lines. By quantification with label-free spectral counting, 89 differentially expressed secreted
proteins (DESPs) between the two cell lines were found. Among them, 57 DESPs were first found to be related to
doxorubicin resistance in this work, including 24 extracellular matrix related proteins, 2 cytokines and 31 unclassified
proteins. We focused on 13 novel DESPs with confirmed roles in tumor metastasis. Among them, the elevated expression of
IL-18 in doxorubicin-resistant cell lines and breast tumor tissues was validated and its role in doxorubicin resistance was
further confirmed by cell viability experiments in the presence or absence of this protein.
Conclusions/Significance: Comparative analysis of the secretome of MCF-7 and MCF-7/Dox identified novel secreted
proteins related to chemotherapy resistance. IL-18 was further validated to contribute to doxorubicin resistance, in addition
to its confirmed role in breast cancer metastasis. Due to its dual roles in both drug resistance and tumor metastasis, IL-18
may represent a useful drug target for breast cancer therapy.
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Introduction
Breast cancer is the most commonly diagnosed type of cancers
among women. Chemotherapy is an important tool in the
treatment of breast cancer. However, chemotherapy often fails
due to drug resistance, especially multidrug resistance. Tumor cells
are found to adopt multiple mechanisms to resist drugs, such as
decreased uptake of drugs and/or enhanced efflux of drugs,
altered metabolism of drugs, alterations in drug targets, activation
of detoxify systems, enhanced DNA repair ability, inhibition of
apoptosis [1]. These identified mechanisms are usually focused on
the changes of membrane proteins and intracellular proteins in
drug resistant tumor cells. The roles of secreted proteins in
chemoresistance have not been clearly demonstrated.
Recently, several lines of evidence indicate that secreted
proteins play critical roles in the acquisition of drug resistance.
Extracellular matrix (ECM) components constitute a major part of
secretome. It is widely reported that cancer cells become relatively
resistant to the cytotoxic agents when cultured on ECM
components, such as type IV collagen, laminin or fibronectin
[2,3]. The adhesion of cancer cells to ECM activates the integrin
dependent pro-survival pathways to increase their drug resistance
ability. Gene screening of drug sensitive and resistant cell lines also
indicates that drug resistance is accompanied by the increased
expression of ECM components. Staunton et al. (2001) generated
gene expression-based classifiers to predict drug response for 232
compounds in 60 human cancer cell lines (the NCI-60) [4].
Strikingly, they discovered that gene expression-based classifiers
for multiple drugs were significantly enriched for genes related to
the cytoskeleton or ECM. For example, the 120-gene classifier for
cytochalasin D resistance included 29 (24%) genes related to the
cytoskeleton or ECM, such as FN1, COL6A1, COL4A1,
COL4A2 and COL6A2. Besides ECM components, other
secreted proteins are also found to contribute to drug resistance.
Arlt et al. (2002) found that culture supernatants from pancreatic
carcinoma drug resistant cell lines could induce the chemosensitive
cells to acquire drug resistance [5]. Several secreted proteins have
been identified to participate in the acquisition of chemoresistance,
including some cytokines and growth factors. Interleukin-6 (IL-6)
was found to cause multidrug resistance in breast cancer cells by
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transcription factors and inducing mdr1 gene expression [6].
Connective tissue growth factor (CTGF) conferred breast cancer
cell drug resistance by augmenting a survival pathway through
ERK1/2-dependent Bcl-xL/cIAP1 up-regulation [7]. In order to
identify drug targets and potential serum biomarkers for clinical
anti-cancer drug response prediction, a systematic screening of
secreted proteins contributed to chemotherapy resistance is highly
desired.
Proteomics provides a promising way to discover drug resistance
related proteins. Both traditional two-dimensional gel electropho-
resis and recently developed approaches, such as liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS), have been
used to explore candidates involved in drug resistance [8,9].
Recent emerging proteomic analysis of serum-free conditioned
media (CM) of cell lines, termed as secretome analysis, provides a
powerful way to identify secreted proteins related to drug
resistance [10–12]. The strategy of one-dimensional gel electro-
phoresis in combination with LC-MS/MS (GeLC-MS/MS) was
widely used in secretome studies [13,14]. The pre-separation of
proteins by SDS-PAGE to reduce sample complexity, followed by
in-gel digestion and LC-MS/MS dramatically increase the
analytical depth in complex samples. The label-free method is
an effective way to semi-quantitate the abundance of detected
proteins in different samples [15]. This method provides a higher
dynamic range for quantification and more analytical depth than
most stable isotope labeling techniques [16].
In the present work, we used the proteomic strategy of GeLC-
MS/MS to compare the secretome between MCF-7 and its
doxorubicin-resistant subcell line (MCF-7/Dox) to identify
secreted proteins related to drug resistance. Doxorubicin is a
DNA intercalating agent that produces free radicals and induces
DNA double-strand breaks by interfering with DNA topoisomer-
ases [17]. By using a proteomic strategy, we identified 1716 and
1261 proteins in the CM of MCF-7 and of MCF-7/Dox,
respectively. Among the identified proteins, 244 were classified
as secreted proteins. In addition, 835 proteins were predicted as
potential secreted proteins by predictive software SignalP 3.0 and
SecretomeP 2.0. We focused on 244 secreted proteins for further
analysis. Based on label-free spectral counting, 89 differentially
expressed secreted proteins (DESPs) between two cell lines were
found. Among them, 57 DESPs have not been previously reported
to be related to doxorubicin resistance. We further validated that
interleukin-18 (IL-18) contributed to doxorubicin resistance.
Considering the confirmed roles of IL-18 in breast cancer
progression and metastasis, our work revealed for the first time
to our knowledge that IL-18 might play dual functions in drug
resistance and tumor metastasis.
Results and Discussion
MS Data Overview
As shown in Figure 1, the CM of MCF-7 and MCF-7/Dox were
collected and analyzed by the proteomic strategy of GeLC-MS/
MS. Three replicates of each cell line were analyzed. Proteins
identified with at least two unique peptides were selected for
further analysis. According to this criterion, a total of 2084
proteins were identified in the CM of two cell lines. As shown in
Figure 2A, 893 proteins (42.9%) were detected in both cell lines,
823 and 368 proteins were only identified in CM of MCF-7 and
MCF-7/Dox, respectively. For MCF-7/Dox, a large portion of
proteins (893 in 1261, 70.8%) was shared with MCF-7.
We further analyzed the subcellular distribution of identified
proteins. Among total 2084 identified proteins, 244 (11.7%) were
classified as secreted proteins (Figure 2C). In addition, 835
(40.1%) proteins were predicted as potential secreted proteins by
predictive software SignalP 3.0 and SecretomeP 2.0. Taken
together, about 50% proteins were classified as secreted proteins
or predicted secreted proteins. Among total 2084 identified
proteins, we also detected 34.1% intracellular proteins. This was
mainly due to the release of intracellular proteins from
unavoidable dead cells during culture process. The proteins
identified in the CM of MCF-7 or MCF-7/Dox showed similar
subcellular distributions (Figure 2D, 2E).
Figure 1. Workflow for the comparative secretome analysis of
MCF-7 and MCF-7/Dox. Illustration of the label-free approach to
identify the differential proteins in the CM of MCF-7 and MCF-7/Dox cell
lines.
doi:10.1371/journal.pone.0024684.g001
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of 244 secreted proteins were identified in the CM of two cell lines,
including 162 identified from MCF-7 and 178 identified from
MCF-7/Dox. The overlap of secreted proteins in two cell lines was
shown in Figure 2B: 96 secreted proteins were detected in both cell
lines, while 66 and 82 secreted proteins were only detected in the
CM of MCF-7 or MCF-7/Dox, respectively.
Identification of Doxorubicin Resistance Related DESPs
Based on spectral counting of unique peptides, we used the
Student’s t-test to identify which of the 244 secreted proteins were
differentially expressed in the two cell lines (p,0.01). We imposed
an additional constraint for secreted proteins with abundance
altered more than 2-fold. According to these criteria, we found 89
DESPs between two cell lines, with 61 up-regulated and 28 down-
regulated in MCF-7/Dox.
The molecular functions of these 89 DESPs were classified
according to Gene Ontology functional annotation. The top three
functions were binding (69, 77.5%), followed by signal transducer
activity (27, 30.3%) and catalytic activity (23, 25.8%) (Figure 3A).
The molecular functions of 13 DESPs (14.6%) were still unknown.
Classification of DESPs
To better understand the roles of these DESPs in the acquisition
of drug resistance, we categorized the 89 DESPs into different
classes, including ECM related proteins, growth factors and
cytokines (Figure 3B). 51 DESPs were categorized into these
groups (Table 1,2,3). The left 38 DESPs were grouped as
unclassified DESPs (Table 4). The detailed information about
the 89 DESPs was listed in supplementary Table S1.
The largest portionof the DESPs were ECM related proteins (44,
49.4%), including 13 ECM components, 14 ECM remodeling
related proteins and 17 proteins which can interact with the ECM
components or contribute to the ECM structure (Table 1). This
finding was consistent with the widely reported roles of ECM in
drug resistance. We found most of the ECM related DESPs (31 of
44, 70.5%) were up-regulated in MCF-7/Dox. We noticed that
among 14 ECMremodelingrelatedproteins, 6 proteins belonged to
the serpin family, including SERPINB2, SERPINE2, SERPING1,
SERPINE1, SERPINA5 and SERPINA3. The serpins are the
largest superfamily of serine protease inhibitors, and are involved in
diverse biological processes, including ECM maintenance and
remodeling, tumor cell invasion, and inflammation [18].
Among the identified DESPs, there were four growth factors,
including CYR61, CTGF, NOV and DKK1 (Table 2). All these
growth factors were only detected in the CM of MCF-7/Dox.
Notably, three growth factors (CYR61, CTGF, NOV) belong to
the same family, namely CCN family [19]. In addition, the
cytokines IL-6, IL-18 and ILEI (FAM3C) were also up-regulated
in MCF-7/Dox (Table 3).
Figure 2. Overview of proteins identified in the CM of MCF-7 and MCF-7/Dox and their subcellular localization. Overlap of total
proteins (A) and secreted proteins (B) identified in the CM of MCF-7 and MCF-7/Dox. (C) Subcellular localization of total proteins identified in the CM
of MCF-7 and MCF-7/Dox. (D, E) Subcellular localization of proteins identified in the CM of MCF-7 and MCF-7/Dox, respectively.
doi:10.1371/journal.pone.0024684.g002
Figure 3. Functional analysis and classification of DESPs. (A) The functional analysis of DESPs between MCF-7 and MCF-7/Dox. (B) The
classification of DESPs between MCF-7 and MCF-7/Dox.
doi:10.1371/journal.pone.0024684.g003
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Gene symbol Spectral counting of peptides P value Rsc
a Ref
b Metastasis
c
MCF-7/Dox MCF-7
Mean ± SD Mean ± SD
ECM components
LAMB1 249.368.8 0.060.0 0.000 7.7 [20]
CSPG4 152.0621.5 0.060.0 0.001 7.0 [22] yes
COL6A2 85.364.9 0.060.0 0.000 6.1 [20]
COL12A1 66.068.5 0.060.0 0.000 5.8 [20]
FBN2 68.3613.1 0.060.0 0.002 5.8 [20]
COL1A1 15.364.1 0.060.0 0.006 3.8 yes
FBN1 6.361.2 0.060.0 0.002 2.6 [20]
LAMA1 578.0614.4 0.760.9 0.000 8.3 [20]
COL6A1 161.3613.7 13.066.4 0.000 3.5 [20]
LAMC1 470.0636.6 116.065.4 0.000 2.0
LAMA5 65.0610.6 175.7618.6 0.002 21.4 [21,22]
COL18A1 1.762.4 71.3620.8 0.009 24.6 yes
COL12A1 0.060.0 218.3631.4 0.001 27.4
ECM remodeling related proteins
ADAMTS1 80.7611.9 0.060.0 0.001 6.1 [29] yes
CTHRC1 26.064.5 0.060.0 0.001 4.5 yes
EXTL2 21.065.0 0.060.0 0.004 4.2
MMP1 2619.36354.4 18.7618.0 0.000 7.1 [23,25,26] yes
TIMP2 166.7631.9 32.0610.8 0.005 2.4 [24]
XYLT1 0.060.0 7.360.5 0.000 22.8
KLK6 0.060.0 34.068.0 0.004 24.8
PRSS23 0.060.0 72.3612.7 0.001 25.9
Serpin Family
SERPINB2 142.3626.6 0.060.0 0.002 6.9 [23]
SERPINE2 90.768.7 0.060.0 0.000 6.2 [28] yes
SERPING1 13.762.9 0.060.0 0.003 3.6
SERPINE1 824.76125.9 1.061.4 0.001 8.6 [23] yes
SERPINA5 26.762.5 11.760.5 0.001 1.1
SERPINA3 0.060.0 177.7628.4 0.001 27.1
Other ECM related proteins
SPARC 532.3629.4 0.060.0 0.000 8.8 [21] yes
NID2 223.369.9 0.060.0 0.000 7.5
MATN2 118.364.2 0.060.0 0.000 6.6
LUM 43.769.2 0.060.0 0.003 5.2 yes
MFGE8 33.769.0 0.060.0 0.006 4.8 [28]
CCDC80 35.363.3 0.060.0 0.000 4.9
ICAM1 18.760.9 0.060.0 0.000 4.0 [42] yes
NID1 6.060.8 0.060.0 0.000 2.6
ECM1 223.3611.0 1.361.9 0.000 6.5 [20,21] yes
COCH 132.765.0 8.762.6 0.000 3.8
LGALS3BP 561.0622.8 81.0616.3 0.000 2.8 [44] yes
THBS1 404.0623.4 1634.36289.4 0.004 22.0 yes
AGRN 83.7614.1 360.0613.1 0.000 22.1 yes
MATN2 0.060.0 17.763.3 0.002 23.9
PXDN 0.060.0 103.7616.9 0.001 26.4
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The DESPs found in this work were extensively compared with
previous studies to identify novel chemoresistance relevant
secreted proteins. The reported proteins were marked in
Table 1,2,3,4.
First, we compared DESPs with doxorubicin resistance related
genes which were found by functional genomics studies [4,20–27].
For example, Iseri et al. (2009) demonstrated the alterations in gene
expression levels of ECM proteins in doxorubicin-resistant MCF-7
cells [20]. Among those proteins, 8 of them coincided with our
identified DESPs, including LAMB1, COL6A2, COL12A1,
FBN2, FBN1, LAMA1, COL6A1 and ECM1. Among the gene
expression signature for doxorubicin resistance based on the NCI-
60 cell line panel [4,21,22], we found 6 proteins overlapped with
our identified DESPs, including CSPG4, LAMA5, ECM1,
SPARC, GSN and PSAP. Then we considered doxorubicin
resistance related genes identified in clinical samples of breast
cancer [28–34]. We found 4 proteins showed similar up-/down-
regulation tendency with our DESPs, including MFGE8, SER-
PINE2, ADAMTS1 and CTGF. Combining these results, a total
of 25 DESPs were previously identified by transcriptional profiling
studies.
Second, we compared our DESPs with doxorubicin resistance
related proteins identified by proteomic studies [8,35–40].
Although differentially expressed proteins between MCF-7 and
its doxorubicin resistant cell were extensively studied by proteomic
methods, the secretome of two cell lines has not been compared.
Among those works, we found no protein overlapped with our
DESPs.
To avoid omission of doxorubicin resistance related proteins
which were identified by other studies, we searched against
PubMed with keywords of ‘‘gene/protein name, drug resistance
and adriamycin/doxorubicin’’ for each of the remaining DESPs.
This analysis identified additional 7 reported DESPs, including
TNFRSF6B [41], ICAM1 [42], MUC16 [43], LGALS3BP [44],
CYR61 [45], NOV [46] and IL-6 [6].
Taken together, among 89 DESPs, 32 have been reported in
previous studies, leaving 57 DESPs as novel identified adriamycin/
doxorubicin resistance related secreted proteins. These 57 novel
identified proteins included 24 ECM related proteins, 2 cytokines
and 31 unclassified proteins.
Secreted Proteins with Potential Dual Functions in Drug
Resistance and Tumor Metastasis
The drug resistance and metastasis of tumor cells have often
been considered and studied as independent events. However,
recent studies indicate that the acquisition of these two abilities are
tightly related. Carcinostatic agents may increase the number and
the growth rate of metastases, which are often more drug resistant
than their primary tumors [47,48]. The drug resistant cancer cells
were found to be more metastatic than their parental cell lines
[49,50]. Several proteins with dual functions in drug resistance
and tumor metastasis have been found in recent years. The
proteins with dual functions are ideal cancer therapeutic targets.
To identify the potential dual functional proteins, 89 DESPs were
searched against PubMed to confirm their roles in tumor
metastasis. We found that 32 DESPs were reported to contribute
to tumor metastasis with the same up- or down-regulation
tendency in drug resistance. As mentioned above, 89 DESPs
identified in this work included 32 drug resistance related proteins
reported in previous work and 57 novel identified proteins. Among
32 reported drug resistance related secreted proteins, 19 were
found to participate in tumor metastasis. Among 57 novel
Gene symbol Spectral counting of peptides P value Rsc
a Ref
b Metastasis
c
MCF-7/Dox MCF-7
Mean ± SD Mean ± SD
HMCN1 0.060.0 380.3694.3 0.005 28.2
FREM2 0.060.0 333.0619.3 0.000 28.0
a RSC: the spectral count fold-change ratio for protein between MCF-7/Dox and MCF-7. It was calculated according to Eq (1).
b references for doxorubicin resistance.
c ‘‘yes’’ indicates the same expression tendency between drug resistance and tumor metastasis.
doi:10.1371/journal.pone.0024684.t001
Table 1. Cont.
Table 2. List of growth factors among the DESPs.
Gene symbol Spectral counting of peptides P value Rsc
a Ref
b Metastasis
c
MCF-7/Dox MCF-7
Mean ± SD Mean ± SD
CTGF 172.0614.9 0.060.0 0.000 7.1 [7,29] yes
CYR61 152.3610.9 0.060.0 0.000 7.0 [45] yes
NOV 50.362.6 0.060.0 0.000 5.4 [46] yes
DKK1 18.065.1 0.060.0 0.008 4.0 [23] yes
a RSC: the spectral count fold-change ratio for protein between MCF-7/Dox and MCF-7. It was calculated according to Eq (1).
b references for doxorubicin resistance.
c ‘‘yes’’ indicates the same expression tendency between drug resistance and tumor metastasis.
doi:10.1371/journal.pone.0024684.t002
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to contribute to tumor metastasis. These 13 proteins have the
potential to be validated as novel dual functional proteins.
We noticed that four growth factors all have confirmed dual
functions in chemoresistance and cancer metastasis. Interestingly,
three growth factors (CYR61, CTGF, NOV) belong to the CCN
family. The CCN family consists of six members: CTGF, NOV,
CYR61, WISP-1, WISP-2, and WISP-3 [19]. Their expression
can promote cellular proliferation, migration, adhesion, and
extracellular matrix formation, as well as the regulation of
angiogenesis and tumorigenesis [7,19]. The function of each
member of CYR61, CTGF, NOV in drug resistance or cancer
metastasis has been reported separately [7,45,46,51–53]. The
activation of some critical pathways by these growth factors
contributes to the acquisition of dual functions in drug resistance
and cancer metastasis. CTGF activates integrin avb3-dependent
ERK1/2 pathway to promote the migration and drug resistance of
breast cancer cells [7,54]. Likewise, CYR61 contributes to breast
cancer cell drug resistance via activation of the integrin avb3/NF-
kB/XIAP signaling pathway [45], and it promotes tumor cell
motility/invasion by an integrin avb3/NF-kB-dependent COX-2
up-regulation pathway [55].
Noteworthy, all three cytokines in our identified DESPs have
confirmed functions in breast cancer metastasis. Among them,
only IL-6 has confirmed function in drug resistance. It has been
reported that IL-6 can confer multiple cancer cells resistance to
chemotherapeutic compounds, such as myeloma [56], prostate
cancer [57], ovarian cancer [58] and breast cancer cells [6]. The
monoclonal antibody of IL-6 has been used as second-line therapy
for men with castration-resistant prostate cancer [59]. However,
the roles of IL-18 and ILEI in drug resistance have not been
demonstrated before.
We used the Ingenuity Pathways Analysis (IPA) software to
demonstrate the networks of the total 32 DESPs with potential
dual functions (Figure 4). It was obvious that IL-6 and IL-18 were
located as centers to link multiple signaling pathways. IL-18
participated in 7 pathways among the top 10 canonical pathways,
including IL-6 signaling pathway, role of macrophages, fibroblasts
and endothelial cells in rheumatoid arthritis pathway, and
atherosclerosis signaling pathway. These signaling pathways are
involved in cellular proliferation, cellular apoptosis, ECM
remodeling, etc., suggesting that IL-18 has the potential to
contribute to drug resistance. However, the role of IL-18 in drug
resistance has not been validated.
Validation the Role of IL-18 in Drug Resistance
IL-18 was discovered as an interferon-c-inducing factor [60]. It
belongs to IL-1 cytokine superfamily [61]. Except its functions in
inflammatory and immune response, it can promote tumor
progression via promoting angiogenesis, promoting tumor growth
and metastasis, and escaping immune response [62]. IL-18 can
promote the metastasis of multiple cancers, such as breast cancer
[63,64], myeloma [65], gastric cancer [66] and leukemia [67]. The
blockade of IL-18 bioactivity can inhibit the lung metastasis of 4T1
breast cancer in mouse model [68]. Clinical data indicate that the
expression level of IL-18 is increased in cancer patients, and
correlated with tumor size, clinical stage, lymph node metastasis,
distant metastasis and prognosis [64]. These evidences indicate
that IL-18 is an important cytokine to promote cancer progression
and metastasis.
We first validated the elevated expression level of IL-18 in
doxorubicin resistant cell lines. Besides MCF-7 and MCF-7/Dox,
another MCF-7 subcell line with higher resistance ability to
doxorubicin (MCF-7/DoxH) was also included in the study. As
shown in Figure 5A, the mRNA level of IL-18 was significantly
increased in MCF-7/Dox (91.9610.6-fold) or MCF-7/DoxH
(78.865.5-fold) compared to MCF-7. We also determined the IL-
18 concentration in the cell lysates and CM in three breast cancer
cell lines. Our results showed that in cell lysates, the concentration
of IL-18 was dramatically increased from 33.465.6 pg/mg total
protein for MCF-7 to 9430.56270.5 pg/mg total protein for
MCF-7/Dox and 9142.46524.6 pg/mg total protein for MCF-7/
DoxH. Accordingly, the secreted IL-18 in the CM was increased
from undetectable for MCF-7 to 215.8619.6 pg/ml for MCF-7/
Dox and 206.4623.2 pg/ml for MCF-7/DoxH (Figure 5B). It is
evident that there is a significant increase in the expression of IL-
18 in two drug resistant cell lines at both mRNA and protein level.
Interestingly, the induction of IL-18 expression was similar in
MCF-7/Dox and MCF-7/DoxH without further elevation with
the increased drug resistance. Considering cytokines, including IL-
18, usually exert biological functions at concentrations as low as
picomolar levels [64], the expression level of IL-18 in MCF-7/Dox
and MCF-7/DoxH may be high enough to exert its function in
doxorubicin resistance. On the other hand, drug resistance is a
complex event involving the changes of hundreds of genes/
proteins which accounting for multiple mechanisms [1,4,27].
Besides the contribution of IL-18 in doxorubicin resistance, the
acquisition of higher doxorubicin resistance ability in MCF-7/
DoxH may require the involvement of other proteins and
mechanisms.
To test if IL-18 plays an important role in drug resistance in
breast cancer patients, we further determined the concentration of
IL-18 in the tumor tissue lysates of 18 breast cancer patients
received neoadjuvant chemotherapy before surgery (Figure 5C). In
12 drug-sensitive tumor lysates, the average concentration of IL-18
was 371.6 pg/mg total protein, ranging from 13.563.1 to
Table 3. List of cytokines among the DESPs.
Gene symbol Spectral counting of peptides P value Rsc
a Ref
b Metastasis
c
MCF-7/Dox MCF-7
Mean ± SD Mean ± SD
IL-6 68.0610.7 0.060.0 0.001 5.8 [6] yes
IL-18 11.361.9 0.060.0 0.001 3.4 yes
ILEI 31.062.2 6.365.3 0.004 2.1 yes
a RSC: the spectral count fold-change ratio for protein between MCF-7/Dox and MCF-7. It was calculated according to Eq (1).
b references for doxorubicin resistance.
c ‘‘yes’’ indicates the same expression tendency between drug resistance and tumor metastasis.
doi:10.1371/journal.pone.0024684.t003
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IL-18 was dramatically increased in 6 drug-resistant tumor lysates,
the average concentration of IL-18 was 1790.3 pg/mg total
protein, ranging from 1168.4697.5 to 2917.36180.8 pg/mg total
protein. All of these results indicated that IL-18 played an
important role in drug resistance.
The role of IL-18 in doxorubicin resistance was further
validated by the increased doxorubicin resistance of MCF-7 in
the presence of recombinant human IL-18 (rIL-18) and decreased
doxorubicin resistance of MCF-7/Dox with the neutralization of
IL-18. As shown in Figure 5D, in the presence of rIL-18, the
survival rate of MCF-7 was significantly increased at doxorubicin
Table 4. List of the remained DESPs.
Gene symbol Spectral counting of peptides P value Rsc
a Ref
b Metastasis
c
MCF-7/Dox MCF-7
Mean ± SD Mean ± SD
PTGDS 193.3637.1 0.060.0 0.002 7.3
MSLN 180.0631.9 0.060.0 0.001 7.2 [26] yes
LOXL2 83.366.8 0.060.0 0.000 6.1 yes
TNFRSF6B 42.761.2 0.060.0 0.000 5.2 [41] yes
AEBP1 42.064.3 0.060.0 0.000 5.1
EPDR1 39.765.4 0.060.0 0.000 5.1
CDA 32.066.7 0.060.0 0.002 4.8
IGFBP6 31.062.9 0.060.0 0.000 4.7
TWSG1 20.761.7 0.060.0 0.000 4.2
IGFBPL1 15.361.7 0.060.0 0.000 3.8
CPA4 14.762.5 0.060.0 0.001 3.7
MUC16 8.061.4 0.060.0 0.001 2.9 [43] yes
FSTL1 255.3627.2 0.760.9 0.000 7.1
C1R 107.7611.9 0.760.9 0.000 5.9
SEMA3D 91.062.2 0.760.9 0.000 5.6
PTX3 260.3633.8 2.763.8 0.000 6.1 [23]
PLA2G15 47.767.6 2.062.8 0.001 3.9
ERAP1 16.063.6 1.061.4 0.005 3.0
NPC2 111.7624.6 9.368.2 0.005 3.4
RNASE4 47.762.1 4.764.6 0.000 3.1
VCL 333.7611.1 48.767.6 0.000 2.8
PSAP 77.769.0 12.060.8 0.001 2.6 [22] yes
TGFBI 142.7622.2 23.364.5 0.002 2.6 yes
TFRC 56.769.5 162.3615.8 0.001 21.5 [30]
RNPEP 24.366.1 79.7611.6 0.004 21.6
CPE 6.360.5 24.363.7 0.002 21.7
CLU 20.361.7 164.765.7 0.000 22.9
RNASET2 7.361.2 62.7614.6 0.006 22.9 yes
GSN 16.062.2 195.3616.8 0.000 23.5 [21,22] yes
SEMA3C 3.361.2 272.0649.4 0.002 25.9
NTN1 0.060.0 12.362.1 0.001 23.4
NUCB2 0.060.0 14.063.7 0.006 23.6
IDE 0.060.0 16.362.4 0.001 23.8 yes
FLRT3 0.060.0 17.763.4 0.002 23.9
METRNL 0.060.0 23.364.5 0.002 24.3
PDGFRL 0.060.0 26.767.7 0.008 24.5 yes
STC1 0.060.0 40.364.0 0.000 25.0
IGFBP2 0.060.0 127.7612.9 0.000 26.7
a RSC: the spectral count fold-change ratio for protein between MCF-7/Dox and MCF-7. It was calculated according to Eq (1).
b references for doxorubicin resistance.
c ‘‘yes’’ indicates the same expression tendency between drug resistance and tumor metastasis.
doi:10.1371/journal.pone.0024684.t004
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doxorubicin concentration of 12.5 ng/mL, the survival rate of
MCF-7 was increased from 65.4%64.6% to 93.4%64.6%
(p,0.01) in the presence of rIL-18. The fifty percent inhibition
of cell proliferation (IC50) of MCF-7 for doxorubicin was elevated
from 24.9 ng/mL to 45.5 ng/mL with the existence of 40.0 ng/
mL rIL-18 in culture medium (Figure S2A). We also tested the
effect of neutralization of IL-18 on the survival of MCF-7/Dox. As
shown in Figure 5E, at the doxorubicin concentration of 200 ng/
mL, the cell viability was decreased from 100%62.8% to
87.3%65.1% (p,0.05) and 83.1%63.9% (p,0.01) with the
existence of 20 and 50 ng/mL anti-IL-18 antibody, respectively.
At the doxorubicin concentration of 2000 ng/mL, the cell viability
was decreased from 34.8%61.9% to 29.8%61.6% (p,0.05) and
22.9%61.6% (p,0.01) with the existence of 20 and 50 ng/mL
anti-IL-18 antibody, respectively. The viability of MCF-7/Dox
was also decreased at other doxorubicin concentrations in a
manner which is dependent on the concentration of anti-IL-18
antibody (Figure S2B). Our results demonstrated that IL-18 also
contributed to drug resistance besides its roles in promoting breast
cancer metastasis. As a secreted protein with dual functions, IL-18
could be an ideal drug target of breast cancer therapy.
Drug resistance and tumor metastasis are the major causes of
chemotherapy failure and mortality in breast cancer patient. The
identification of proteins with dual functions in drug resistance
and tumor metastasis is critical for understanding the linkage
between these two processes and designing better drugs and
therapeutic strategies. As ideal drug targets, the discovery of
secreted proteins with dual functions is highly desired. In this
work, we presented 13 secreted proteins with potential dual
functions and demonstrated for the first time to our knowledge
that IL-18 might play dual functions in drug resistance and breast
cancer metastasis.
Conclusion
In the present work, we compared the secretome of MCF-7/
Dox and MCF-7 to identify doxorubicin resistance related
secreted proteins. We found 89 DESPs between the two cell
lines. Noteworthy 57 DESPs were first found to be related to
doxorubicin resistance in this work. Among them, 13 DESPs
have been reported to participate in tumor metastasis. These
13 DESPs were potential novel dual-functional proteins, with
confirmed role in tumor metastasis and unvalidated role in
drug resistance. One of them, IL-18, was further validated to
contribute to doxorubicin resistance. As a newly identified
protein with dual functions in drug resistance and breast
cancer metastasis, IL-18 is a promising target for cancer
therapy.
Figure 4. Canonical pathways analysis of DESPs with potential dual functions in drug resistance and tumor metastasis. 32 DESPs with
dual functions were analyzed by software IPA. The top 10 canonical pathways were mapped onto the DESPs, such as IGF-1 signaling, acute phase
response signaling and IL-6 signaling etc. IL-6 and IL-18 were located as centers to link multiple signaling pathways.
doi:10.1371/journal.pone.0024684.g004
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Ethics Statement
Human breast cancer tissue samples were obtained from the
Ruijin Hospital, Shanghai Jiao Tong University, upon the
approval of the Scientific and Ethical Committee of Shanghai
Jiao Tong University. The written informed consent was obtained
from all patients. The study was conducted according to the
principle of the Helsinki Declaration. Data were analyzed
anonymously.
Cell lines, tumor tissues and reagents
The breast cancer cell line MCF-7 was purchased from the
American Type Culture Collection. MCF-7/Dox and MCF-7/
DoxH were purchased from Nanjing KeyGen Biotech. Co. Ltd,
China. MCF-7/Dox and MCF-7/DoxH were developed from
sensitive MCF-7 by stepwise selection in increasing concentrations of
doxorubicin. MCF-7/Dox and MCF-7/DoxH showed 35-fold, 265-
fold increase in doxorubicin resistance compared to MCF-7,
respectively (Figure S1A and S1B). The method of the drug resistant
characteristic assay of MCF-7/Dox and MCF-7/DoxH is described
in Text S1. The 18 post-chemotherapy breast tumor tissue samples
were obtained from patients received four cycles of cyclophospha-
mide - doxorubicin - 5-fluorouracil before surgery. Responses to
chemotherapy were classified according to the UICC criteria [69].
Partial response (PR) was defined as a reduction of at least 50% in
measurable tumor lesions and no new lesions appears, progressive
disease(PD) was defined as a 25% or more increase in the measurable
lesions or the appearance of new tumor lesions. We defined the
tumors with response PR as drug-sensitive samples and the tumors
with response PD as drug-resistant samples. The information of
patients was shown in supplementary Table S2. RPMI medium 1640
was purchased from Gibco. Doxorubicin was purchased from
Zhejiang Hisun Pharmaceutical Co., China. All other chemicals,
unless indicated otherwise in the text, were from Sigma-Aldrich. The
highest available grades were used throughout the study.
Cell Culture
MCF-7 cell line was cultured in RPMI medium 1640
supplemented with 10% fetal bovine serum, penicillin (40 kU/L)
and streptomycin (40 mg/L) at 37uCi n5 %C O 2. MCF-7/Dox
and MCF-7/DoxH were cultured in the same medium with
additional supplement of 200 ng/mL and 1000 ng/mL doxoru-
bicin, respectively.
Figure 5. Validation of the expression level of IL-18 and its role in drug resistance. (A) The mRNA level of IL-18 in MCF-7, MCF-7/Dox and
MCF-7/DoxH. The amount of IL-18 mRNA was normalized against the expression of GAPDH and the data were presented as mean 6 SD (n=3).
**, p,0.01. (B) The concentration of IL-18 in the CM of MCF-7, MCF-7/Dox and MCF-7/DoxH. The data were presented as mean 6 SD (n=3).
**, p,0.01. (C) The expression level of IL-18 in the lysates of 18 breast tumor tissues, including 12 drug-sensitive tissues and 6 drug-resistant tissues.
The data were presented as mean 6 SD (n=3). **, p,0.01. (D) The doxorubicin dose dependent survival rate of MCF-7 in the absence or presence of
40 ng/mL rIL-18. Data were presented as mean 6 SD (n=3). **, p,0.01. (E) The effect of anti-IL-18 neutralization on the survival rate of MCF-7/Dox.
Data were presented as mean 6 SD (n=3). *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0024684.g005
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When cells were grown to approximately 75% confluence in
10 cm culture dishes, the culture medium was changed to serum
free conditioned medium (CM). As described previously [70], we
optimized the cell wash procedure to avoid the contamination of
remained bovine serum. The cells were rinsed with serum free
medium at 37uC for 15 min twice and then 60 min twice. Then the
cells were incubated in the serum free medium at 37uC for 24 h.
The cell death rate was usually under 3%. The CM of each cell line
was collected, centrifuged at 1,500 rpm for 10 min, filtrated by
0.22 mm filter, and then added protease inhibitor cocktail (Roche,
Mannheim, Germany) before being stored at 280uC.
Three replicates of CM from 8.0610
6 cells for each cell line
were concentrated by the Ultra-15 centrifugal filter devices with a
3 kDa cutoff (Millipore, Bedford, MA). The protein concentration
of concentrated samples was determined by Bradford assay. Then
these samples were lyophilized for further analysis.
One-dimensional Gel Electrophoresis and In-gel
Digestion
Three replicates of concentrated CM for each cell line were
separated on the 12% SDS-PAGE gel, and stained with
Coomassie Blue. After extensive decolorization, each gel lane
was excised into 13 sections. Each excised section was cut into
approximately 1 mm cubes and destained by incubation in 50%
acetonitrile in 50 mM ammonium bicarbonate. After destained,
the gel pieces were reduced by incubation in a solution of 50 mM
tris (2-carboxyethyl) phosphine in 25 mM ammonium bicarbonate
at 60uC for 10 min. For alkylation of proteins, the gel was
incubated in a solution of 100 mM iodoacetamide at room
temperature for 60 min, followed by washing the sample using
50% acetonitrile in 50 mM ammonium bicarbonate for three
times. After dehydrated in 100% acetonitrile for 15 min, gel pieces
were completely dried by SpeedVac. Then the gel pieces were
swollen in 50 mL of 25 mM ammonium bicarbonate buffer
containing 0.01 mg/mL trypsin (Promega, Madison, WI) and
incubated overnight at 37uC. Peptides were extracted with 50%
acetonitrile containing 5% formic acid four times, dried by
vacuum centrifugation at 60uC, and stored at 220uC for further
analysis.
Nano LC-MS/MS
The tryptic peptide digests of the proteins were analyzed using
an MDLC system (Michrom Bioresources Inc., Auburn, CA)
coupled with a Thermo Finnigan 2-D linear ion trap mass
spectrometer (LTQ
XL, Thermo Inc., San Jose, CA). Each peptide
sample was re-dissolved in 5% acetonitrile with 0.1% formic acid,
and then loaded onto a Peptide Captrap column (Michrom
Bioresources Inc., Auburn, CA) with the autosampler of the
MDLC system. To desalt and concentrate the sample, the trap
column was washed with 5% acetonitrile with 0.1% formic acid at
a flow rate of 10 mL/min for 10 min. Then trapped peptides were
released and separated on a C18 capillary column (0.1 mm
i.d.6150 mm, 3 mm, 200 A ˚, Michrom Bioresources Inc., Auburn,
CA). The peptides were separated using a solvent system with
solvent A consisting of 99.9% water and 0.1% formic acid, and
solvent B consisting of 99.9% acetonitrile and 0.1% formic acid.
The peptides were eluted with linear gradient from 5% B to 35%
B in 120 min with a constant flow rate of 500 nL/min. The LC
setup was coupled online to a LTQ using a nano-ESI source
(ADVANCE, Michrom Bioresources Inc., Auburn, CA) in data-
dependent acquisition mode (m/z 400–1800). The temperature of
heated capillary was set at 200uC and spray voltage was 1.2 kV.
The mass spectrometer was set as one full MS scan followed by ten
MS/MS scans on the ten most intense ions from the MS spectrum
with the following dynamic exclusion settings: repeat count=2,
repeat duration=15 s, exclusion duration=30 s.
Protein Identification
All data files were created by searching MS/MS spectra against
the Human International Protein Index protein sequence database
(IPI.Human.v3.63.fasta, 84118 entries), by using the TurboSE-
QUEST program in the BioWorks 3.3 software suite, with a
precursor-ion mass tolerance of 2.0 amu and fragment-ion mass
tolerance of 1.0 amu. Trypsin was set as the protease with
two missed cleavage sites allowed. Carbamidomethylation
(+57.02150 Da) was searched as a fixed modification on cysteine,
representing alkylation with iodoacetamide, while oxidized methi-
onine (+15.99492 Da) was searched as a variable modification. The
searched peptides and proteins were validated by PeptideProphet
and ProteinProphet in the Trans-Proteomic Pipeline (TPP, v.4.2)
using default parameters. Proteins with ProteinProphet P value
greater than 0.9 and with no less than two kinds of unique peptides
were considered as true identifications. A randomized database of
the IPI.Human.v3.63.fasta was used as a decoy database to
calculate the false discovery rate (FDR) of protein identification.
The FDR was calculated by the ratio of the number of matches to
therandomizeddatabasetothecombinednumberofmatchestothe
IPI.Human.v3.63.fasta and its randomized derivative. FDR for
ProteinProphet P$0.9 was less than 1%. Proteins containing the
same peptides were grouped, and only one protein with highest
probability in each group was remained.
Bioinformatics Analysis
The proteins identified with at least two unique peptides were
selected for further analysis. Spectral counts of unique peptides
were used for protein quantification. The data were further
analyzed with SPSS 14.0 software. Student’s t-test was used to
select data sets from two groups with statistical significance. To
compare the relative abundance of each protein between MCF-7/
Dox and MCF-7, we calculate the spectral count fold-change
ratios (RSC) using following algorithm [15,71]:
RSC~log2 n2zf ðÞ = n1zf ðÞ ½  zlog2 t1{n1zf ðÞ = t2{n2zf ðÞ ½  ,ð1Þ
where for each protein, RSC is the log2 ratio of protein abundance
between MCF-7/Dox and MCF-7; n1 and n2 are the average of
spectral counts of this protein in three replicates for MCF-7 and
MCF-7/Dox, respectively. t1 and t2 are the average of total
spectral counts of all proteins in three replicates for MCF-7 and
MCF-7/Dox, respectively, and f is a correction factor set to 1.25.
The localizations of the identified proteins were classified as
secreted, predicted secreted, plasma membrane and intracellular.
Every protein was assigned a most possible location. To designate
proteins as secreted proteins, the subcellular information was
obtained from the PIPE (http://pipe.systemsbiology.net/) and
UniProtKB. The predicted secreted proteins were predicted by
SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) with D-
score higher than 0.43 and a higher hidden Markov matrix score
than 0.9 [72,73] and SecretomeP 2.0 (http://www.cbs.dtu.dk/
services/SecretomeP/) with NNscore higher than 0.5 [74]. The
subcellular information of remained proteins was obtained from
the PIPE and UniProtKB.
The information of the molecular function of the selected
proteins was obtained from Gene Ontology. The canonical
pathways of the selected DESPs were analyzed with software IPA.
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Total RNAs were extracted from cultured cells using a RNeasy
mini kit according to the manufacturer’s instruction (Tiangen,
Beijing, China). Primers for real-time PCR were designed using
Primer Express software version 2.0 (Applied Biosystems, Foster
City, California, USA) and synthesized by Invitrogen (Invitrogen,
Shanghai, China). The primer sequences for IL-18 are 59-
CAAGGAAATCGGCCTCTATTTG-39 (forward) and 59-
GCCATACCTCTAGGCTGGCTAT-39 (reverse). The primer
sequences for internal control glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) are 59-CATGAGAAGTATGACAA-
CAGCCT-39 (forward) and 59-AGTCCTTCCACGATAC-
CAAAGT-39 (reverse). Real-time quantitative PCR was done in
an Applied Biosystems 7300 Real-Time PCR System (Applied
Biosystems, Foster City, California, USA) using SYBR Green
diction according to the manufacturer’s instruction. The amount
of IL-18 mRNA was normalized against the expression of
GAPDH.
ELISA
The concentrations of IL-18 in the cell lines and clinical samples
were determined by using a commercial ELISA kit according to
the manufacturer’s instruction (MBL, Nagoya, Japan). To prepare
the CM, 1610
6 cells were seeded on 10 cm dishes. When cells
were grown to approximately 75% confluence, cells were further
cultured in 7.5 mL serum free medium for 24 h and the CM was
collected as described above. To prepare the cell lysates, cells were
collected and lysed in lysis buffer (50 mM Tris-HCl, 100 mM
NaCl, 1% NP40, protease inhibitor cocktail, pH 7.4). To prepare
the breast cancer tissue lysates, the tissues were homogenized and
lysed in lysis buffer. The lysates were then centrifuged at
13,000 rpm for 60 min, the supernatant was collected and stored
at 280uC. The protein concentrations of cell/tissue lysates were
determined by Bicinchoninic Acid (BCA) assay.
Cell Viability Assay
To test the survival rate of MCF-7 in the presence of rIL-18,
1.0610
5 MCF-7 cells were seeded on 3.5 cm dishes. After 24 h
incubation, cells were treated with different doses of doxorubicin
in the presence or absence of 40 ng/mL rIL-18 (ProSpec-Tany
TechnoGene, Rehovot, Israel). Three parallel samples were
repeated for each concentration point of doxorubicin. After 72 h
incubation, the cells were digested and viable cells were counted
by trypan blue exclusion (PBS, 0.4% trypan blue) with a blood cell
count board. Either supplied with rIL-18 or not, the cell survival
rate was calculated by the ratio of cell numbers at different doses of
doxorubicin to that in the absence of doxorubicin. The IC50 was
calculated by fitted equation using OriginPro 8 software. To test
the effect of anti-IL-18 neutralization on the survival rate of MCF-
7/Dox, 1.0610
5 MCF-7/Dox cells were seeded on 3.5 cm dishes.
After 24 h incubation, cells were treated with different doses of
doxorubicin in the presence or absence of 20 or 50 ng/mL anti-
IL-18 antibody (MBL, Nagoya, Japan). After 96 h incubation, the
cells were digested and viable cells were counted by trypan blue
exclusion with a blood cell count board. Either with or without
anti-IL-18 antibody, the cell survival rate was calculated by the
ratio of cell numbers at different doses of doxorubicin to that of
200 ng/mL doxorubicin. All the cell viability experiments were
repeated three times as indicated using triplicate samples for cell
counting analyses. Data were evaluated using the Student’s t-test
and were considered significant when p,0.05.
Supporting Information
Figure S1 The drug resistant characteristic of MCF-7/
Dox (A) and MCF-7/DoxH (B). The cell survival rates of each
cell line at different concentrations of doxorubicin were deter-
mined and presented as mean 6 SD (n=3).
(TIF)
Figure S2 The validation of the role of IL-18 in
doxorubicin resistance. (A) The curves of doxorubicin dose
dependent survival rate of MCF-7 in the absence or presence of
40 ng/mL rIL-18. Data were presented as mean 6 SD (n=3). **,
p,0.01. (B) The effect of anti-IL-18 neutralization on the survival
rate of MCF-7/Dox. Data were presented as mean 6 SD (n=3).
*, p,0.05, **, p,0.01.
(TIF)
Table S1 The detailed information about the 89 DESPs
between MCF-7 and MCF-7/Dox.
(XLS)
Table S2 The information of breast cancer patients.
(XLS)
Text S1 The method of the drug resistant characteristic
assay of MCF-7/Dox and MCF-7/DoxH.
(DOC)
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